Rare disease biotech Fulcrum Therapeutics sets terms for $77 million IPO

Shutterstock photo

Fulcrum Therapeutics, a Phase 1 biotech developing therapies based on gene regulation for rare diseases, announced terms for its IPO on Monday.

The Cambridge, MA-based company plans to raise $77 million by offering 4.5 million shares at a price range of $16 to $18. At the midpoint of the proposed range, Fulcrum Therapeutics would command a fully diluted market value of $411 million.

Fulcrum Therapeutics was founded in 2016 and it plans to list on the Nasdaq under the symbol FULC. Morgan Stanley, BofA Merrill Lynch and SVB Leerink are the joint bookrunners on the deal. It is expected to price during the week of July 15, 2019.

The article Rare disease biotech Fulcrum Therapeutics sets terms for $77 million IPO originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.

Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital's Renaissance IPO ETF (symbol: IPO) , Renaissance International ETF (symbol: IPOS) , or separately managed institutional accounts may have investments in securities of companies mentioned.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

This article appears in: News Headlines , IPOs

More from Renaissance Capital


Renaissance Capital

Renaissance Capital


Research Brokers before you trade

Want to trade FX?